Tebentafusp is designed to target the melanoma-associated antigen gp100 through a high-affinity T-cell receptor binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells (38). Here, PMEL is linked to neoplasm.